Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -9.76% and 24.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 102.6% in Orchestra BioMed Holdings, Inc. (OBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of 5% and 51.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 18.18% and 6.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -12.90% and 9.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 5% and 1.20%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season
by Zacks Equity Research
Orchestra BioMed (OBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.